Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 397

1.

Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy.

van De Ven NS, Pozniak AL, Levi JA, Clayden P, Garratt A, Redd C, Mofenson LM, Hill A.

Clin Infect Dis. 2019 Oct 9. pii: ciz684. doi: 10.1093/cid/ciz684. [Epub ahead of print]

PMID:
31595301
2.

Magnetic resonance-guided direct shoulder arthrography for the detection of superior labrum anterior-posterior lesions using an open 1.0-T MRI scanner.

Berth A, Pozniak A, Stendel L, Fischbach F, Lohmann C, Pech M.

Pol J Radiol. 2019 May 20;84:e251-e257. doi: 10.5114/pjr.2019.86894. eCollection 2019.

3.

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naïve HIV-1 Infected Adults with Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance Mutations.

Wong A, Goldstein D, Mallolas J, DeJesus E, Johnson M, Molina JM, Pozniak A, Rodgers A, Teal V, Hepler D, Kumar S, Sklar P, Hanna GJ, Hwang C, Badshah C, Teppler H.

J Acquir Immune Defic Syndr. 2019 Aug 16. doi: 10.1097/QAI.0000000000002153. [Epub ahead of print] No abstract available.

PMID:
31425317
4.

Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?

Rockwood N, Cerrone M, Barber M, Hill AM, Pozniak AL.

J Int AIDS Soc. 2019 Jul;22(7):e25333. doi: 10.1002/jia2.25333.

5.

Dolutegravir-rilpivirine for virological suppression.

Pozniak AL, Arribas JR.

Lancet HIV. 2019 Sep;6(9):e560-e561. doi: 10.1016/S2352-3018(19)30188-2. Epub 2019 Jul 12. No abstract available.

PMID:
31307947
6.

Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.

Mofenson LM, Pozniak AL, Wambui J, Raizes E, Ciaranello A, Clayden P, Ehrenkranz P, Fakoya A, Hill A, Khoo S, Mahaka I, Modi S, Moore C, Phillips A, Siberry G, Sikwese K, Thorne C, Watts HD, Doherty M, Ford NP.

J Int AIDS Soc. 2019 Jul;22(7):e25352. doi: 10.1002/jia2.25352.

7.

Most new HIV infections, vertical transmissions and AIDS-related deaths occur in lower-prevalence countries.

Kempton J, Hill A, Levi JA, Heath K, Pozniak A.

J Virus Erad. 2019 Apr 1;5(2):92-101.

8.

Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials.

Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M.

AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.

9.

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.

Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, Maartens G, Pozniak A, Flexner C, Boffito M.

J Antimicrob Chemother. 2019 Jun 1;74(6):1670-1678. doi: 10.1093/jac/dkz068.

PMID:
30815689
10.

Are new antiretroviral treatments increasing the risks of clinical obesity?

Hill A, Waters L, Pozniak A.

J Virus Erad. 2019 Jan 1;5(1):41-43.

11.

High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with men.

Pool E, Winston A, Bagkeris E, Vera JH, Mallon P, Sachikonye M, Post FA, Pozniak A, Boffito M, Anderson J, Williams I, Johnson M, Burgess L, Sabin CA; Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study team.

HIV Med. 2019 Feb;20(2):131-136. doi: 10.1111/hiv.12690. Epub 2018 Dec 12.

12.

Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction.

Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS, Murphy G, Asboe D, Pozniak A, Kirk S, Gill ON, Sabin C, Delpech V, Dunn DT; UK HIV Drug Resistance Database .

Clin Infect Dis. 2019 Sep 13;69(7):1136-1143. doi: 10.1093/cid/ciy1048.

PMID:
30534981
13.

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.

Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A.

Lancet HIV. 2019 Feb;6(2):e116-e127. doi: 10.1016/S2352-3018(18)30317-5. Epub 2018 Nov 29.

14.
15.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.

Ammassari A, Stöhr W, Antinori A, Molina JM, Schwimmer C, Domingo P, Thalme A, Di Pietro M, Wallet C, Pozniak A, Richert L, Raffi F; NEAT001/ANRS143 Trial Study Group.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):481-490. doi: 10.1097/QAI.0000000000001834.

16.

Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.

George EC, Bucciardini R, Richert L, Dedes N, Fragola V, Nieuwkerk P, Spire B, Volny-Anne A, West B, Molina JM, Horban A, Fox J, Pozniak A, Vella S, Termote M, Raffi F; NEAT 001/ANRS 143 Study Group.

J Acquir Immune Defic Syndr. 2018 Dec 1;79(4):519-526. doi: 10.1097/QAI.0000000000001844.

PMID:
30234665
17.

Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined with Either Raltegravir or Tenofovir Disoproxil Fumarate /Emtricitabine in the Neat 001/Anrs 143 Trial.

Ammassari A, Stöhr W, Antinori A, Molina JM, Schwimmer C, Domingo P, Thalme A, Di Pietro M, Wallet C, Pozniak A, Richert L, Raffi F; and the NEAT 001/ANRS 143 Trial Study Group.

J Acquir Immune Defic Syndr. 2018 Aug 27. doi: 10.1097/QAI.0000000000001834. [Epub ahead of print]

PMID:
30153121
18.

Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission.

Bekker LG, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, Dybul M, Eholie S, Esom K, Garnett G, Grimsrud A, Hakim J, Havlir D, Isbell MT, Johnson L, Kamarulzaman A, Kasaie P, Kazatchkine M, Kilonzo N, Klag M, Klein M, Lewin SR, Luo C, Makofane K, Martin NK, Mayer K, Millett G, Ntusi N, Pace L, Pike C, Piot P, Pozniak A, Quinn TC, Rockstroh J, Ratevosian J, Ryan O, Sippel S, Spire B, Soucat A, Starrs A, Strathdee SA, Thomson N, Vella S, Schechter M, Vickerman P, Weir B, Beyrer C.

Lancet. 2018 Jul 28;392(10144):312-358. doi: 10.1016/S0140-6736(18)31070-5. Epub 2018 Jul 20. Review. No abstract available.

19.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group .

Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505.

PMID:
29912307
20.

Non-disclosed men who have sex with men in UK HIV transmission networks: phylogenetic analysis of surveillance data.

Ragonnet-Cronin M, Hué S, Hodcroft EB, Tostevin A, Dunn D, Fawcett T, Pozniak A, Brown AE, Delpech V, Brown AJL; UK HIV Drug Resistance Database.

Lancet HIV. 2018 Jun;5(6):e309-e316. doi: 10.1016/S2352-3018(18)30062-6.

PMID:
29893244
21.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings.

Revell AD, Wang D, Perez-Elias MJ, Wood R, Cogill D, Tempelman H, Hamers RL, Reiss P, van Sighem AI, Rehm CA, Pozniak A, Montaner JSG, Lane HC, Larder BA; RDI Data and Study Group.

J Antimicrob Chemother. 2018 Aug 1;73(8):2186-2196. doi: 10.1093/jac/dky179.

22.

Trends in, and factors associated with, HIV infection amongst tuberculosis patients in the era of anti-retroviral therapy: a retrospective study in England, Wales and Northern Ireland.

Winter JR, Stagg HR, Smith CJ, Lalor MK, Davidson JA, Brown AE, Brown J, Zenner D, Lipman M, Pozniak A, Abubakar I, Delpech V.

BMC Med. 2018 Jun 7;16(1):85. doi: 10.1186/s12916-018-1070-2.

23.
24.
25.

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.

Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P; UK HIV Drug Resistance Database; UK Collaborative HIV Cohort.

AIDS Res Ther. 2018 Apr 16;15(1):11. doi: 10.1186/s12981-018-0198-7.

26.

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.

Ryom L, Boesecke C, Bracchi M, Ambrosioni J, Pozniak A, Arribas J, Behrens G, Mallon P, Puoti M, Rauch A, Miro JM, Kirk O, Marzolini C, Lundgren JD, Battegay M; EACS Governing Board.

HIV Med. 2018 May;19(5):309-315. doi: 10.1111/hiv.12600. Epub 2018 Mar 1.

27.

HIV Drug Resistance.

Beyrer C, Pozniak A.

N Engl J Med. 2018 Mar 1;378(9):875. doi: 10.1056/NEJMc1716089. No abstract available.

PMID:
29490186
28.

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Barber TJ, Imaz A, Boffito M, Niubó J, Pozniak A, Fortuny R, Alonso J, Davies N, Mandalia S, Podzamczer D, Gazzard B.

J Neurovirol. 2018 Jun;24(3):388-389. doi: 10.1007/s13365-017-0613-1.

PMID:
29318452
29.

CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Barber TJ, Imaz A, Boffito M, Niubó J, Pozniak A, Fortuny R, Alonso J, Davies N, Mandalia S, Podzamczer D, Gazzard B.

J Neurovirol. 2018 Feb;24(1):98-105. doi: 10.1007/s13365-017-0600-6. Epub 2017 Dec 26. Erratum in: J Neurovirol. 2018 Jan 9;:.

PMID:
29280108
30.

Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials.

Hill AM, Mitchell N, Hughes S, Pozniak AL.

Curr Opin HIV AIDS. 2018 Mar;13(2):102-111. doi: 10.1097/COH.0000000000000445. Review.

PMID:
29278532
31.

The Dialysis Facility Compare Five-Star Rating System at 2 Years.

Pozniak A, Pearson J.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):474-476. doi: 10.2215/CJN.11231017. Epub 2017 Dec 18. No abstract available.

32.

Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.

Jackson A, Else L, Higgs C, Karolia Z, Khoo S, Back D, Devitt E, Pozniak A, Boffito M.

HIV Clin Trials. 2018 Feb;19(1):31-37. doi: 10.1080/15284336.2017.1408928. Epub 2017 Nov 30.

PMID:
29189101
33.

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.

Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S; Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.

Lancet HIV. 2018 Mar;5(3):e146-e154. doi: 10.1016/S2352-3018(17)30190-X. Epub 2017 Nov 22.

34.

Auxeticity of Yukawa Systems with Nanolayers in the (111) Crystallographic Plane.

Pigłowski PM, Narojczyk JW, Poźniak AA, Wojciechowski KW, Tretiakov KV.

Materials (Basel). 2017 Nov 22;10(11). pii: E1338. doi: 10.3390/ma10111338.

35.

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*.

AIDS. 2017 Nov 28;31(18):2503-2514. doi: 10.1097/QAD.0000000000001675.

36.

HIV Drug Resistance - An Emerging Threat to Epidemic Control.

Beyrer C, Pozniak A.

N Engl J Med. 2017 Oct 26;377(17):1605-1607. doi: 10.1056/NEJMp1710608. No abstract available.

37.

Rapidly declining HIV infection in MSM in central London.

Nwokolo N, Hill A, McOwan A, Pozniak A.

Lancet HIV. 2017 Nov;4(11):e482-e483. doi: 10.1016/S2352-3018(17)30181-9. Epub 2017 Oct 20. No abstract available.

PMID:
29066095
38.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E.

Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.

PMID:
28867499
39.

Injecting drug use predicts active tuberculosis in a national cohort of people living with HIV.

Winter JR, Stagg HR, Smith CJ, Brown AE, Lalor MK, Lipman M, Pozniak A, Skingsley A, Kirwan P, Yin Z, Thomas HL, Delpech V, Abubakar I.

AIDS. 2017 Nov 13;31(17):2403-2413. doi: 10.1097/QAD.0000000000001635.

40.

Disseminated aspergillosis in an HIV-positive cannabis user taking steroid treatment.

Salam AP, Pozniak AL.

Lancet Infect Dis. 2017 Aug;17(8):882. doi: 10.1016/S1473-3099(17)30438-3. No abstract available.

PMID:
28741551
41.

The science of Durban, AIDS 2016.

Beyrer C, Shisana O, Baral SD, Milsana K, Mayer KH, Pozniak A, Walker BD, Mboup S, Sohn AH, Serwadda D, Rees H, Dvoriak S, Warren M, Thiam S, El-Sadr WM, Hospital X, Ryan O, Thomson N, Bekker LG.

J Int AIDS Soc. 2017 Jun 30;20(1):21781. doi: 10.7448/IAS.20.1.21781.

42.

Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.

Pozniak A, Flamm J, Antinori A, Bloch M, Ward D, Berenguer J, Cote P, Andreatta K, Garner W, Szwarcberg J, Nguyen-Cleary T, McColl DJ, Piontkowsky D.

HIV Clin Trials. 2017 Jul;18(4):141-148. doi: 10.1080/15284336.2017.1338844. Epub 2017 Jul 9.

PMID:
28689453
43.

The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.

Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM, Post FA, Hill T, Kirk O, Pozniak A, Nelson M, Tostevin A, Dunn D, Lundgren J, Cozzi-Lepri A.

Antivir Ther. 2018;23(2):105-116. doi: 10.3851/IMP3178.

PMID:
28627486
44.

Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades.

Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A.

BMJ Glob Health. 2016 Sep 15;1(2):e000010. doi: 10.1136/bmjgh-2015-000010. eCollection 2016.

45.

Antiretroviral dose optimization: the future of efavirenz 400 mg dosing.

Boffito M, Lamorde M, Watkins M, Pozniak A.

Curr Opin HIV AIDS. 2017 Jul;12(4):339-342. doi: 10.1097/COH.0000000000000385. Review.

PMID:
28570367
46.

When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.

Vitoria M, Ford N, Clayden P, Pozniak AL, Hill AM.

Curr Opin HIV AIDS. 2017 Jul;12(4):414-422. doi: 10.1097/COH.0000000000000380. Review.

47.

Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.

Gotham D, Hill A, Pozniak AL.

Curr Opin HIV AIDS. 2017 Jul;12(4):324-333. doi: 10.1097/COH.0000000000000379. Review.

PMID:
28403027
48.

Cutting the cost of South African antiretroviral therapy using newer, safer drugs.

Venter WF, Kaiser B, Pillay Y, Conradie F, Gomez GB, Clayden P, Matsolo M, Amole C, Rutter L, Abdullah F, Abrams EJ, Casas CP, Barnhart M, Pillay A, Pozniak A, Hill A, Fairlie L, Boffito M, Moorhouse M, Chersich M, Serenata C, Quevedo J, Loots G.

S Afr Med J. 2016 Dec 21;107(1):28-30. doi: 10.7196/SAMJ.2016.v107.i1.12058.

49.

Estimated generic prices for novel treatments for drug-resistant tuberculosis.

Gotham D, Fortunak J, Pozniak A, Khoo S, Cooke G, Nytko FE 3rd, Hill A.

J Antimicrob Chemother. 2017 Apr 1;72(4):1243-1252. doi: 10.1093/jac/dkw522.

50.

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A, Pillay D, Dunn DT; UK HIV Drug Resistance Database; (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees; UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2016 Dec;71(12):3487-3494. Epub 2016 Sep 28.

Supplemental Content

Loading ...
Support Center